Table 1. Catalog of previous reports of HIP1-ALK+ lung cancer.
| No. | Year | Chromosomal location | Fusion breakpoint | Response to ALK-TKI | Tumor source | Detection method | VAF | FISH/IHC | References |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 2014 | 7q11.23 | (H28:A20) | Not treated with ALK TKI (PDX crizotinib sensitive) | Tumor | RNA NGS | NR | ND/ND | Douglas D. Fang, et al. |
| 2 | 2014 | 7q11.23 | (H21:A20) | PR to crizotinib | Tumor | RT-PCR | NR | +/+ | Mineui Hong, et al. |
| 3 | 2014 | 7q11.23 | (H30: A20) | PR to crizotinib & alectinib | Tumor | DNA NGS | NR | +/ND | Sai-Hong Ignatius Ou, et al. |
| 4 | 2016 | – | (H19:A20) | Not treated with ALK TKI | – | – | NR | +/+ | Jin Sung Jang, et al. |
| 5 | 2019 | 7q11.23 | (H28:A20) | PR to crizotinib (PFS 26.9 m) | Tumor | DNA NGS (WES) | NR | ND/ND | Mathilde Couëtoux du Tertre, et al. |
| 6 | 2020 | 7q11.23 | (H22:A21) | PR to crizotinib (PFS 7.0 m) | Tumor | DNA NGS | NR | ND/ND | Panwen Tian, et al. |
| 7 | 2021 | 7q11.23 | (H19:A20) | NR to crizotinib; PR to alectinib | Tumor | DNA NGS | 1.67% | ND/+ | Mengnan Li, et al. |
+, positive. HIP1, huntingtin-interacting protein 1; ALK, anaplastic lymphoma kinase; TKI, tyrosine kinase inhibitor; NGS, next-generation sequencing; RT-PCR, reverse transcriptase polymerase chain reaction; WES, whole exome sequencing; VAF, variant frequency; FISH, fluorescent in situ hybridization; IHC, immunochemistry; NR, not reported; ND, not detected.